Scientific Research News

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharma Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®...

BOSTON--(BUSINESS WIRE)--nChroma Bio, a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced new preclinical data presented at The Liver Meeting® 2025 of the American Association for the Study of Liver Diseases (AASLD). The results, including a Poster of Distinction, highlight the potential of the company’s lead candidate, CRMA-1001, to deliver a functional cure for chronic hepatitis B virus (HBV) through a...

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dechra, a global leader in veterinary specialty care, announced today its status as the newest Human-Animal Bond Certified Company....

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the following investor conferences in November. UBS Global Healthcare Conference Date / Time: November 10th Format: 1x1’s Location:...

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2025. Third Quarter 2025 Results: Revenue of $84.1 million, growing 17% year-over-year GAAP loss of $6.6 million, or ($0.21) per share Non-GAAP income of $4.5 million, or $0.14 per share Adjusted EBI...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 88,300 shares of the company’s common stock to 4 new employees (the “...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biomunex Pharmaceuticals announces presentation of preclinical data from its MAIT engager platform at the SITC 40th Annual Meeting...

SHANGHAI--(BUSINESS WIRE)--Evinova and Harbour BioMed announced a strategic collaboration in artificial intelligence to build an open ecosystem for AI-driven drug R&D....

LOS ANGELES--(BUSINESS WIRE)--City of Hope today announced that Dr. Christine M. Lovly will spearhead the development of its new national thoracic oncology program starting Jan. 1....

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 21, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 184,961 shares of its common stock to 272 new non-executive employees and one non-qualified stock option award to purchase 5,731 shares of its common stock to one new non-executive employee with a grant date of Octobe...